{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:39:34Z","timestamp":1793943574638,"version":"4.8.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Childhood idiopathic nephrotic syndrome is an important pediatric kidney disease associated with significant morbidities and even mortality. Several guidelines have been developed to standardize the terminology and patient care among the pediatric nephrology community. Since the publication of these guidelines, there have been major breakthroughs in the disease management and the understanding of underlying pathogenesis through multi-omics investigations, including the identification of anti-nephrin autoantibodies, genetic susceptibility loci, and the pathogenic role of B cell subsets. In this educational review, we summarize the recent major advancements in idiopathic nephrotic syndrome and attempt to provide potential therapeutic approaches in both steroid-sensitive and steroid-resistant nephrotic syndrome that may shape future guideline development.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s00467-024-06634-9","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T10:00:03Z","timestamp":1735207203000},"page":"2431-2442","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Childhood idiopathic nephrotic syndrome: recent advancements shaping future guidelines"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-6005","authenticated-orcid":false,"given":"Eugene Yu-hin","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3957-1359","authenticated-orcid":false,"given":"Olivia","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"key":"6634_CR1","doi-asserted-by":"publisher","unstructured":"Veltkamp F, Rensma LR, Bouts AH (2021) Incidence and relapse of idiopathic nephrotic syndrome: Meta-analysis. Pediatrics 148:e2020029249. https:\/\/doi.org\/10.1542\/peds.2020-029249","DOI":"10.1542\/peds.2020-029249"},{"key":"6634_CR2","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0140-6736(23)01051-6","volume":"402","author":"M Vivarelli","year":"2023","unstructured":"Vivarelli M, Gibson K, Sinha A, Boyer O (2023) Childhood nephrotic syndrome. Lancet 402:809\u2013824","journal-title":"Lancet"},{"key":"6634_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2215\/CJN.02560315","volume":"11","author":"DS Gipson","year":"2016","unstructured":"Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K (2016) Complete remission in the nephrotic syndrome study network. Clin J Am Soc Nephrol 11:81","journal-title":"Clin J Am Soc Nephrol"},{"key":"6634_CR4","doi-asserted-by":"publisher","first-page":"l1800","DOI":"10.1136\/bmj.l1800","volume":"365","author":"N Webb","year":"2019","unstructured":"Webb N, Woolley R, Lambe T, Frew E, Brettell E, Barsoum E, Trompeter R, Cummins C, Deeks J, Wheatley K (2019) Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation. BMJ 365:l1800","journal-title":"BMJ"},{"key":"6634_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ekir.2019.12.015","volume":"5","author":"SA Carter","year":"2020","unstructured":"Carter SA, Mistry S, Fitzpatrick J, Banh T, Hebert D, Langlois V, Pearl RJ, Chanchlani R, Licht CP, Radhakrishnan S (2020) Prediction of short-and long-term outcomes in childhood nephrotic syndrome. Kidney Int Rep 5:426\u2013434","journal-title":"Kidney Int Rep"},{"key":"6634_CR6","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00431-017-2891-2","volume":"176","author":"G Desch\u00eanes","year":"2017","unstructured":"Desch\u00eanes G, Vivarelli M, Peruzzi L (2017) Variability of diagnostic criteria and treatment of idiopathic nephrotic syndrome across European countries. Eur J Pediatr 176:647\u2013654","journal-title":"Eur J Pediatr"},{"key":"6634_CR7","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00467-022-05739-3","volume":"38","author":"A Trautmann","year":"2023","unstructured":"Trautmann A, Boyer O, Hodson E, Bagga A, Gipson DS, Samuel S, Wetzels J, Alhasan K, Banerjee S, Bhimma R (2023) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 38:877\u2013919","journal-title":"Pediatr Nephrol"},{"key":"6634_CR8","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00467-020-04519-1","volume":"35","author":"A Trautmann","year":"2020","unstructured":"Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, Hui NK, Boyer O, Saleem MA, Feltran L (2020) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 35:1529\u20131561","journal-title":"Pediatr Nephrol"},{"key":"6634_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/j.ajkd.2022.05.013","volume":"81","author":"M Marlais","year":"2023","unstructured":"Marlais M, Wlodkowski T, Printza N, Kronsteiner D, Krisam R, Sauer L, Aksenova M, Ashoor I, Awan A, Bacchetta J (2023) Clinical factors and adverse kidney outcomes in children with antineutrophil cytoplasmic antibody\u2013associated glomerulonephritis. Am J Kidney Dis 81:119\u2013122","journal-title":"Am J Kidney Dis"},{"key":"6634_CR10","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/ndt\/gfae009","volume":"39","author":"K Rohner","year":"2024","unstructured":"Rohner K, Marlais M, Ahn YH, Ali A, Alsharief A, Novak AB, Brambilla M, Cakici EK, Candan C, Canpolat N (2024) Outcome of immunosuppression in children with IgA vasculitis\u2013related nephritis. Nephrol Dial Transplant 39:1299\u20131309","journal-title":"Nephrol Dial Transplant"},{"key":"6634_CR11","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2215\/CJN.13371019","volume":"15","author":"AE Mason","year":"2020","unstructured":"Mason AE, Sen ES, Bierzynska A, Colby E, Afzal M, Dorval G, Koziell AB, Williams M, Boyer O, Welsh GI (2020) Response to first course of intensified immunosuppression in genetically stratified steroid resistant nephrotic syndrome. Clin J Am Soc Nephrol 15:983\u2013994","journal-title":"Clin J Am Soc Nephrol"},{"key":"6634_CR12","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1093\/ndt\/gfad128","volume":"38","author":"K Tullus","year":"2023","unstructured":"Tullus K (2023) Why FSGS keeps being presented as a disease although it is not. Nephrol Dial Transplant 38:2426\u20132427","journal-title":"Nephrol Dial Transplant"},{"key":"6634_CR13","doi-asserted-by":"publisher","first-page":"7682","DOI":"10.1038\/s41467-023-43504-8","volume":"14","author":"T-A Al-Aubodah","year":"2023","unstructured":"Al-Aubodah T-A, Aoudjit L, Pascale G, Perinpanayagam MA, Langlais D, Bitzan M, Samuel SM, Piccirillo CA, Takano T (2023) The extrafollicular B cell response is a hallmark of childhood idiopathic nephrotic syndrome. Nat Commun 14:7682","journal-title":"Nat Commun"},{"key":"6634_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.kint.2022.10.023","volume":"103","author":"LH Mariani","year":"2023","unstructured":"Mariani LH, Eddy S, AlAkwaa FM, McCown PJ, Harder JL, Nair V, Eichinger F, Martini S, Ademola AD, Boima V (2023) Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis. Kidney Int 103:565\u2013579","journal-title":"Kidney Int"},{"key":"6634_CR15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1681\/ASN.2021060794","volume":"33","author":"AJ Watts","year":"2022","unstructured":"Watts AJ, Keller KH, Lerner G, Rosales I, Collins AB, Sekulic M, Waikar SS, Chandraker A, Riella LV, Alexander MP (2022) Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J Am Soc Nephrol 33:238\u2013252","journal-title":"J Am Soc Nephrol"},{"key":"6634_CR16","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.kint.2023.11.022","volume":"105","author":"Y Shirai","year":"2024","unstructured":"Shirai Y, Miura K, Ishizuka K, Ando T, Kanda S, Hashimoto J, Hamasaki Y, Hotta K, Ito N, Honda K (2024) A multi-institutional study found a possible role of anti-nephrin antibodies in post-transplant focal segmental glomerulosclerosis recurrence. Kidney Int 105:608\u2013617","journal-title":"Kidney Int"},{"key":"6634_CR17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa2314471","volume":"391","author":"FE Hengel","year":"2024","unstructured":"Hengel FE, Dehde S, Lass\u00e9 M, Zahner G, Seifert L, Schnarre A, Kretz O, Demir F, Pinnschmidt HO, Grahammer F (2024) Autoantibodies targeting nephrin in podocytopathies. N Eng J Med 391:422\u2013433","journal-title":"N Eng J Med"},{"key":"6634_CR18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","volume":"97","author":"EY-H Chan","year":"2020","unstructured":"Chan EY-H, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma AL-T, Yamamura T, Sinha A, Bagga A, Hogan J (2020) Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int 97:393\u2013401. https:\/\/doi.org\/10.1016\/j.kint.2019.09.033","journal-title":"Kidney Int"},{"key":"6634_CR19","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1038\/s41467-023-37985-w","volume":"14","author":"A Barry","year":"2023","unstructured":"Barry A, McNulty MT, Jia X, Gupta Y, Debiec H, Luo Y, Nagano C, Horinouchi T, Jung S, Colucci M (2023) Multi-population genome-wide association study implicates immune and non-immune factors in pediatric steroid-sensitive nephrotic syndrome. Nat Commun 14:2481","journal-title":"Nat Commun"},{"key":"6634_CR20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00467-017-3819-9","volume":"33","author":"G Dorval","year":"2018","unstructured":"Dorval G, Gribouval O, Martinez-Barquero V, Machuca E, T\u00eate M-J, Baudouin V, Benoit S, Chabchoub I, Champion G, Chauveau D (2018) Clinical and genetic heterogeneity in familial steroid-sensitive nephrotic syndrome. Pediatr Nephrol 33:473\u2013483","journal-title":"Pediatr Nephrol"},{"key":"6634_CR21","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/ndt\/gfaa221","volume":"37","author":"G Dorval","year":"2022","unstructured":"Dorval G, Servais A, Boyer O (2022) The genetics of steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant 37:648\u2013651","journal-title":"Nephrol Dial Transplant"},{"key":"6634_CR22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ajhg.2018.12.016","volume":"104","author":"G Dorval","year":"2019","unstructured":"Dorval G, Kuzmuk V, Gribouval O, Welsh GI, Bierzynska A, Schmitt A, Miserey-Lenkei S, Koziell A, Haq S, Benmerah A (2019) TBC1D8B loss-of-function mutations lead to X-linked nephrotic syndrome via defective trafficking pathways. Am J Hum Genet 104:348\u2013355","journal-title":"Am J Hum Genet"},{"key":"6634_CR23","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1007\/s00431-022-04581-x","volume":"181","author":"L Nandlal","year":"2022","unstructured":"Nandlal L, Winkler CA, Bhimma R, Cho S, Nelson GW, Haripershad S, Naicker T (2022) Causal and putative pathogenic mutations identified in 39% of children with primary steroid-resistant nephrotic syndrome in South Africa. Eur J Pediatr 181:3595\u20133606","journal-title":"Eur J Pediatr"},{"key":"6634_CR24","doi-asserted-by":"publisher","first-page":"885178","DOI":"10.3389\/fmed.2022.885178","volume":"9","author":"X Zhu","year":"2022","unstructured":"Zhu X, Zhang Y, Yu Z, Yu L, Huang W, Sun S, Li Y, Wang M, Li Y, Sun L (2022) The clinical and genetic features in Chinese children with steroid-resistant or early-onset nephrotic syndrome: a multicenter cohort study. Front Med 9:885178","journal-title":"Front Med"},{"key":"6634_CR25","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ (2021) Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int 100:753\u2013779","journal-title":"Kidney Int"},{"key":"6634_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2014.354","volume":"87","author":"PF Hoyer","year":"2015","unstructured":"Hoyer PF (2015) New lessons from randomized trials in steroid-sensitive nephrotic syndrome: clear evidence against long steroid therapy. Kidney Int 87:17\u201319","journal-title":"Kidney Int"},{"key":"6634_CR27","doi-asserted-by":"publisher","first-page":"l1800","DOI":"10.1136\/bmj.l1800","volume":"365","author":"N Webb","year":"2019","unstructured":"Webb N, Woolley R, Lambe T, Frew E, Brettell E, Barsoum E, Trompeter R, Cummins C, Deeks J, Wheatley K, PREDNOS Collaborative Group (2019) Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation. BMJ 365:l1800","journal-title":"BMJ"},{"issue":"gfac103","key":"6634_CR28","first-page":"002","volume":"37","author":"C Dossier","year":"2022","unstructured":"Dossier C, Kwon T, Nekrouf C, Bensaid P, Parmentier C, Galerne A, Chace A, Gobet S, Nathanson S, Mahdi F (2022) FC038: efficacy of levamisole for maintaining remission after the first flare of steroid sensitive nephrotic syndrome in children: the nephrovir-3 randomized controlled trial. Nephrol Dial Transplant 37(gfac103):002","journal-title":"Nephrol Dial Transplant"},{"key":"6634_CR29","doi-asserted-by":"publisher","first-page":"e024882","DOI":"10.1136\/bmjopen-2018-024882","volume":"8","author":"R Ehren","year":"2018","unstructured":"Ehren R, Benz MR, Doetsch J, Fichtner A, Gellermann J, Haffner D, H\u00f6cker B, Hoyer PF, K\u00e4stner B, Kemper MJ (2018) Initial treatment of steroid-sensitive idiopathic nephrotic syndrome in children with mycophenolate mofetil versus prednisone: protocol for a randomised, controlled, multicentre trial (INTENT study). BMJ Open 8:e024882","journal-title":"BMJ Open"},{"key":"6634_CR30","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ekir.2024.02.1395","volume":"9","author":"J Liu","year":"2024","unstructured":"Liu J, Deng F, Wang X, Liu C, Sun S, Zhang R, Zhang A, Jiang X, Yan W, Dou Y (2024) Early rituximab as an add-on therapy in children with the initial episode of nephrotic syndrome. Kidney Int Rep 9:1220\u20131227","journal-title":"Kidney Int Rep"},{"key":"6634_CR31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.kint.2020.09.024","volume":"99","author":"A Gargiulo","year":"2021","unstructured":"Gargiulo A, Massella L, Ruggiero B, Rav\u00e0 L, Degli Atti MC, Materassi M, Lugani F, Benetti E, Morello W, Molino D (2021) Results of the PROPINE randomized controlled study suggest tapering of prednisone treatment for relapses of steroid sensitive nephrotic syndrome is not necessary in children. Kidney Int 99:475\u2013483","journal-title":"Kidney Int"},{"key":"6634_CR32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2215\/CJN.06140420","volume":"16","author":"D Kainth","year":"2021","unstructured":"Kainth D, Hari P, Sinha A, Pandey S, Bagga A (2021) Short-duration prednisolone in children with nephrotic syndrome relapse: a noninferiority randomized controlled trial. Clin J Am Soc Nephrol 16:225\u2013232","journal-title":"Clin J Am Soc Nephrol"},{"key":"6634_CR33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00467-023-05974-2","volume":"39","author":"FF-Y Lai","year":"2024","unstructured":"Lai FF-Y, Chan EY-H, Tullus K, Ma AL-T (2024) Therapeutic drug monitoring in childhood idiopathic nephrotic syndrome: a state of the art review. Pediatr Nephrol 39:85\u2013103. https:\/\/doi.org\/10.1007\/s00467-023-05974-2","journal-title":"Pediatr Nephrol"},{"key":"6634_CR34","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.kint.2024.01.028","volume":"105","author":"A Sinha","year":"2023","unstructured":"Sinha A, Devi KG, Kalra S, Kalaivani M, Hari P, Bagga A (2023) Alternate-day prednisolone given daily during infections vs. levamisole in frequently relapsing nephrotic syndrome: an open label non-inferiority RCT. Kidney Int 105:1113\u20131123","journal-title":"Kidney Int"},{"key":"6634_CR35","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.kint.2024.01.030","volume":"105","author":"EY-H Chan","year":"2024","unstructured":"Chan EY-H, Boyer O (2024) Levamisole in childhood idiopathic nephrotic syndrome: new promises, and advocacy for global access. Kidney Int 105:932\u2013934. https:\/\/doi.org\/10.1016\/j.kint.2024.01.030","journal-title":"Kidney Int"},{"key":"6634_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2215\/CJN.08570722","volume":"18","author":"EY-H Chan","year":"2023","unstructured":"Chan EY-H, Yap DY-H, Colucci M, Ma AL-T, Parekh RS, Tullus K (2023) Use of rituximab in childhood idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 18:533\u2013548. https:\/\/doi.org\/10.2215\/CJN.08570722","journal-title":"Clin J Am Soc Nephrol"},{"key":"6634_CR37","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1007\/s00467-023-06025-6","volume":"38","author":"EY-H Chan","year":"2023","unstructured":"Chan EY-H, Wong S-W, Lai FF-Y, Ho T-W, Tong P-C, Lai W-M, Ma AL-T, Yap DY-H (2023) Long-term outcomes with rituximab as add-on therapy in severe childhood-onset lupus nephritis. Pediatr Nephrol 38:4001\u20134011. https:\/\/doi.org\/10.1007\/s00467-023-06025-6","journal-title":"Pediatr Nephrol"},{"key":"6634_CR38","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/kead447","volume":"63","author":"EY-H Chan","year":"2024","unstructured":"Chan EY-H, Yap DY-H, Wong WH-S, Wong S-W, Lin KY-K, Hui FY-W, Li JY-M, Lam SS-Y, Wong JK-Y, Lai FF-Y (2024) Renal relapse in children and adolescents with childhood-onset lupus nephritis: a 20-year study. Rheumatology (Oxford) 63:953\u2013961. https:\/\/doi.org\/10.1093\/rheumatology\/kead447","journal-title":"Rheumatology (Oxford)"},{"key":"6634_CR39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ekir.2022.10.014","volume":"8","author":"EY-H Chan","year":"2023","unstructured":"Chan EY-H, Yap DY-H, Wong W-T, Wong WH-S, Wong S-W, Lin KY-K, Hui FY-W, Yee-Ming J, Lam SS-Y, Wong JK-Y (2023) Long-term outcomes of children and adolescents with biopsy-proven childhood-onset lupus nephritis. Kidney Int Rep 8:141\u2013150","journal-title":"Kidney Int Rep"},{"key":"6634_CR40","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s00467-020-04609-0","volume":"36","author":"EY-H Chan","year":"2021","unstructured":"Chan EY-H, Tullus K (2021) Rituximab in children with steroid sensitive nephrotic syndrome: in quest of the optimal regimen. Pediatr Nephrol 36:1397\u20131405. https:\/\/doi.org\/10.1007\/s00467-020-04609-0","journal-title":"Pediatr Nephrol"},{"key":"6634_CR41","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1681\/ASN.2015050523","volume":"27","author":"M Colucci","year":"2016","unstructured":"Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Rav\u00e0 L, Ruggiero B, Emma F, Vivarelli M (2016) B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol 27:1811\u20131822","journal-title":"J Am Soc Nephrol"},{"key":"6634_CR42","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.kint.2023.06.013","volume":"104","author":"M Colucci","year":"2023","unstructured":"Colucci M, Angeletti A, Zotta F, Carsetti R, Lugani F, Rav\u00e0 L, Ravani P, Emma F, Ghiggeri GM, Vivarelli M (2023) Age and memory B cells at baseline are associated with risk of relapse and memory B-cell reappearance following anti-CD20 treatment in pediatric frequently-relapsing\/steroid-dependent nephrotic syndrome. Kidney Int 104:577\u2013586","journal-title":"Kidney Int"},{"key":"6634_CR43","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1016\/j.ekir.2022.08.006","volume":"7","author":"A Angeletti","year":"2022","unstructured":"Angeletti A, Bruschi M, Colucci M, Kajana X, La Porta E, Caridi G, Lugani F, Ravani P, Vivarelli M, Cravedi P (2022) Circulating anti-rituximab antibodies do not affect response to rituximab in steroid-dependent nephrotic syndrome. Kidney Int Rep 7:2509\u20132512","journal-title":"Kidney Int Rep"},{"key":"6634_CR44","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1007\/s00467-021-05135-3","volume":"36","author":"R Ehren","year":"2021","unstructured":"Ehren R, Benz MR, Brinkk\u00f6tter PT, D\u00f6tsch J, Eberl WR, Gellermann J, Hoyer PF, Jordans I, Kamrath C, Kemper MJ (2021) Pediatric idiopathic steroid-sensitive nephrotic syndrome: diagnosis and therapy\u2014short version of the updated German best practice guideline (S2e)\u2014AWMF register no. 166\u2013001, 6\/2020. Pediatr Nephrol 36:2971\u20132985","journal-title":"Pediatr Nephrol"},{"key":"6634_CR45","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00467-021-04983-3","volume":"37","author":"F Zotta","year":"2022","unstructured":"Zotta F, Vivarelli M, Emma F (2022) Update on the treatment of steroid-sensitive nephrotic syndrome. Pediatr Nephrol 37:303\u2013314","journal-title":"Pediatr Nephrol"},{"key":"6634_CR46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4103\/ajpn.ajpn_34_21","volume":"4","author":"A Sinha","year":"2021","unstructured":"Sinha A, Bagga A, Banerjee S, Mishra K, Mehta A, Agarwal I, Uthup S, Saha A, Mishra OP (2021) Steroid sensitive nephrotic syndrome: revised guidelines. Asian J Pediatr Nephrol 4:48\u201366","journal-title":"Asian J Pediatr Nephrol"},{"key":"6634_CR47","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1681\/ASN.2021111472","volume":"33","author":"EY-H Chan","year":"2022","unstructured":"Chan EY-H, Ellen L, Angeletti A, Arslan Z, Basu B, Boyer O, Chan C-Y, Colucci M, Dorval G, Dossier C (2022) Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study. J Am Soc Nephrol 33:1193\u20131207. https:\/\/doi.org\/10.1681\/ASN.2021111472","journal-title":"J Am Soc Nephrol"},{"key":"6634_CR48","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00467-021-05345-9","volume":"37","author":"EY-H Chan","year":"2022","unstructured":"Chan EY-H, Ma AL-T, Tullus K (2022) Hypogammaglobulinaemia following rituximab therapy in childhood nephrotic syndrome. Pediatr Nephrol 37:927\u2013931. https:\/\/doi.org\/10.1007\/s00467-021-05345-9","journal-title":"Pediatr Nephrol"},{"key":"6634_CR49","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1007\/s00467-024-06371-z","volume":"39","author":"EY-H Chan","year":"2024","unstructured":"Chan EY-H (2024) Rituximab-induced hypogammaglobulinemia in nephrotic syndrome: what is the true burden? Pediatr Nephrol 39:3129. https:\/\/doi.org\/10.1007\/s00467-024-06371-z","journal-title":"Pediatr Nephrol"},{"key":"6634_CR50","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1007\/s00467-023-05913-1","volume":"38","author":"A Zurowska","year":"2023","unstructured":"Zurowska A, Drozynska-Duklas M, Topaloglu R, Bouts A, Boyer O, Shenoy M, Vivarelli M (2023) Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey. Pediatr Nephrol 38:3035\u20133042","journal-title":"Pediatr Nephrol"},{"key":"6634_CR51","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1007\/s00467-024-06379-5","volume":"39","author":"EY-H Chan","year":"2024","unstructured":"Chan EY-H (2024) Clinical significance of rituximab-associated hypogammaglobulinemia in nephrotic syndrome: to treat or not to treat? Pediatr Nephrol 39:3621. https:\/\/doi.org\/10.1007\/s00467-024-06379-5","journal-title":"Pediatr Nephrol"},{"key":"6634_CR52","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1681\/ASN.2021050643","volume":"33","author":"K Iijima","year":"2022","unstructured":"Iijima K, Sako M, Oba M, Tanaka S, Hamada R, Sakai T, Ohwada Y, Ninchoji T, Yamamura T, Machida H (2022) Mycophenolate mofetil after rituximab for childhood-onset complicated frequently-relapsing or steroid-dependent nephrotic syndrome. J Am Soc Nephrol 33:401\u2013419","journal-title":"J Am Soc Nephrol"},{"key":"6634_CR53","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s00467-021-05176-8","volume":"37","author":"C-s Wang","year":"2022","unstructured":"Wang C-s, Troost JP, Wang Y, Greenbaum LA, Gibson K, Trachtman H, Srivastava T, Reidy K, Kaskel F, Sethna CB (2022) Determinants of medication adherence in childhood nephrotic syndrome and associations of adherence with clinical outcomes. Pediatr Nephrol 37:1585\u20131595","journal-title":"Pediatr Nephrol"},{"key":"6634_CR54","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.3389\/fimmu.2019.01653","volume":"10","author":"M Colucci","year":"2019","unstructured":"Colucci M, Carsetti R, Serafinelli J, Rocca S, Massella L, Gargiulo A, Lo Russo A, Capponi C, Cotugno N, Porzio O (2019) Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome. Front Immunol 10:1653","journal-title":"Front Immunol"},{"key":"6634_CR55","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1016\/j.ekir.2023.08.014","volume":"8","author":"D Leung","year":"2023","unstructured":"Leung D, Chan EY-H, Mu X, Duque JSR, Cheng SM, Ho FT-W, Tong P-C, Lai W-M, Lee MH, Chim S (2023) Humoral and cellular immunogenicity of 3 doses of BNT162b2 in children with kidney diseases. Kidney Int Rep 8:2356\u20132367. https:\/\/doi.org\/10.1016\/j.ekir.2023.08.014","journal-title":"Kidney Int Rep"},{"key":"6634_CR56","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.kint.2022.01.035","volume":"101","author":"AL-T Ma","year":"2022","unstructured":"Ma AL-T, Leung D, Chan EY-H, Chim S, Cheng S, Ho FT-W, Lai W-M, Tong P-C, Lee MH-L, Wong WH-S (2022) Antibody responses to 2 doses of mRNA COVID-19 vaccine in pediatric patients with kidney diseases. Kidney Int 101:1069\u20131072. https:\/\/doi.org\/10.1016\/j.kint.2022.01.035","journal-title":"Kidney Int"},{"key":"6634_CR57","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1016\/j.ekir.2023.08.012","volume":"8","author":"EY-H Chan","year":"2023","unstructured":"Chan EY-H, Leung D, Cheng SM, Duque JSR, Mu X, Ho FT-W, Tong P-C, Lai W-M, Lee MH, Chim S (2023) Humoral and cellular immunogenicity and safety of 3-dose inactivated COVID-19 vaccine in young children less than 5 years with kidney diseases. Kidney Int Rep 8:2177\u20132179. https:\/\/doi.org\/10.1016\/j.ekir.2023.08.012","journal-title":"Kidney Int Rep"},{"key":"6634_CR58","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","volume":"58","author":"TH Ramwadhdoebe","year":"2019","unstructured":"Ramwadhdoebe TH, van Baarsen LG, Boumans MJ, Bruijnen ST, Safy M, Berger FH, Semmelink JF, van der Laken CJ, Gerlag DM, Thurlings RM (2019) Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. Rheumatology (Oxford) 58:1075\u20131085","journal-title":"Rheumatology (Oxford)"},{"key":"6634_CR59","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1111\/ajt.12220","volume":"13","author":"EG Kamburova","year":"2013","unstructured":"Kamburova EG, Koenen HJ, Borgman KJ, Ten Berge I, Joosten I, Hilbrands LB (2013) A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function. Am J Transplant 13:1503\u20131511","journal-title":"Am J Transplant"},{"key":"6634_CR60","doi-asserted-by":"publisher","first-page":"e1436","DOI":"10.1097\/TXD.0000000000001436","volume":"9","author":"CM Looney","year":"2023","unstructured":"Looney CM, Schroeder A, Tavares E, Garg J, Schindler T, Vincenti F, Redfield RR, Jordan SC, Busque S, Woodle ES (2023) Obinutuzumab effectively depletes key B-cell subsets in blood and tissue in end-stage renal disease patients. Transplant Direct 9:e1436","journal-title":"Transplant Direct"},{"key":"6634_CR61","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.2215\/CJN.0000000000000555","volume":"19","author":"X Hu","year":"2024","unstructured":"Hu X, Zhang M, Xu J, Gao C, Yu X, Li X, Ren H, Wang W, Xie J (2024) Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy. Clin J Am Soc Nephrol 19:1594\u20131602","journal-title":"Clin J Am Soc Nephrol"},{"key":"6634_CR62","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1681\/ASN.20203110S153b","volume":"31","author":"BH Rovin","year":"2020","unstructured":"Rovin BH, Martinez GA, Alvarez A, Zuta AE, Furie R, Brunetta PG, Schindler T, Hassan I, Cascino M, Garg JP (2020) Two-year results from a randomized, controlled study of obinutuzumab for proliferative lupus nephritis: SU-OR31. J Am Soc Neohrol 31:53","journal-title":"J Am Soc Neohrol"},{"key":"6634_CR63","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2215\/CJN.0000000000000288","volume":"18","author":"C Dossier","year":"2023","unstructured":"Dossier C, Bonneric S, Baudouin V, Kwon T, Prim B, Cambier A, Couderc A, Moreau C, Deschenes G, Hogan J (2023) Obinutuzumab in frequently relapsing and steroid-dependent nephrotic syndrome in children. Clin J Am Soc Nephrol 18:1555\u20131562","journal-title":"Clin J Am Soc Nephrol"},{"key":"6634_CR64","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-024-06570-8","author":"EY-H Chan","year":"2024","unstructured":"Chan EY-H, Lin KY-K, Yap DY-H, Ma AL-T (2024) Obinutuzumab as a viable therapeutic strategy in rituximab-refractory childhood frequently relapsing, steroid-dependent nephrotic syndrome that relapsed during B-cell depletion. Pediatr Nephrol. https:\/\/doi.org\/10.1007\/s00467-024-06570-8","journal-title":"Pediatr Nephrol"},{"key":"6634_CR65","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40272-023-00609-3","volume":"26","author":"EY-H Chan","year":"2023","unstructured":"Chan EY-H, Lai FF-Y, Ma AL-T, Chan TM (2023) Managing lupus nephritis in children and adolescents. Pediatr Drugs 26:145\u2013161. https:\/\/doi.org\/10.1007\/s40272-023-00609-3","journal-title":"Pediatr Drugs"},{"key":"6634_CR66","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00467-021-05175-9","volume":"37","author":"M Vivarelli","year":"2022","unstructured":"Vivarelli M, Colucci M, Gargiulo A, Bettini C, Lo Russo A, Emma F (2022) Belimumab for the treatment of children with frequently relapsing nephrotic syndrome: the BELNEPH study. Pediatr Nephrol 37:377\u2013383","journal-title":"Pediatr Nephrol"},{"key":"6634_CR67","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","volume":"97","author":"E Crickx","year":"2020","unstructured":"Crickx E, Weill J-C, Reynaud C-A, Mah\u00e9vas M (2020) Anti-CD20\u2013mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives. Kidney Int 97:885\u2013893","journal-title":"Kidney Int"},{"key":"6634_CR68","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1136\/annrheumdis-2023-eular.2442","volume":"82","author":"K Shah","year":"2023","unstructured":"Shah K, Klein C, Cambridge G, Sen D, Castelino M, Akbar A, Isenberg D, Leandro M, Reddy V (2023) AB0017 How do B cells evade rituximab therapy in autoimmunity; is it time to target the CD19+ CD20-B cells? Ann Rheum Dis 82:1187","journal-title":"Ann Rheum Dis"},{"key":"6634_CR69","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.ekir.2024.04.006","volume":"9","author":"A Angeletti","year":"2024","unstructured":"Angeletti A, Bin S, Kajana X, Spinelli S, Bigatti C, Caridi G, Candiano G, Lugani F, Verrina EE, La Porta E (2024) Combined rituximab and daratumumab treatment in difficult-to-treat nephrotic syndrome cases. Kidney Int Rep 9:1892\u20131896","journal-title":"Kidney Int Rep"},{"key":"6634_CR70","doi-asserted-by":"publisher","first-page":"e169424","DOI":"10.1172\/jci.insight.169424","volume":"8","author":"M Vivarelli","year":"2023","unstructured":"Vivarelli M, Colucci M, Algeri M, Zotta F, Emma F, L\u2019Erario I, Busutti M, Rota S, Capelli C, Introna M (2023) A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome. JCI Insight 8:e169424","journal-title":"JCI Insight"},{"key":"6634_CR71","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.ekir.2024.03.031","volume":"9","author":"D Borzych-Du\u017ca\u0142ka","year":"2024","unstructured":"Borzych-Du\u017ca\u0142ka D, Same R, Neu A, Yap HK, Verrina E, Bakkaloglu SA, Cano F, Patel H, Szczepa\u0144ska M, Obrycki \u0141 (2024) Best practice of peritoneal dialysis-associated gram-negative peritonitis in children: insights from the International Pediatric Peritoneal Dialysis Network Registry. Kidney Int Rep 9:1654\u20131663. https:\/\/doi.org\/10.1016\/j.ekir.2024.03.031","journal-title":"Kidney Int Rep"},{"key":"6634_CR72","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/nep.14007","volume":"27","author":"EYH Chan","year":"2022","unstructured":"Chan EYH, Yap DYH, Wong WHS, Ho TW, Tong PC, Lai WM, Chan TM, Ma ALT (2022) Demographics and long-term outcomes of children with end-stage kidney disease: a 20-year territory-wide study. Nephrology (Carlton) 27:171\u2013180. https:\/\/doi.org\/10.1111\/nep.14007","journal-title":"Nephrology (Carlton)"},{"key":"6634_CR73","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1681\/ASN.2016101121","volume":"28","author":"A Trautmann","year":"2017","unstructured":"Trautmann A, Schnaidt S, Lipska-Zi\u0119tkiewicz BS, Bodria M, Ozaltin F, Emma F, Anarat A, Melk A, Azocar M, Oh J (2017) Long-term outcome of steroid-resistant nephrotic syndrome in children. J Am Soc Nephrol 28:3055\u20133065","journal-title":"J Am Soc Nephrol"},{"key":"6634_CR74","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1007\/s00467-022-05828-3","volume":"38","author":"EY-H Chan","year":"2023","unstructured":"Chan EY-H, Liu M-S, Or P-C, Ma AL-T (2023) Outcomes and perception of cloud-based remote patient monitoring in children receiving automated peritoneal dialysis: a prospective study. Pediatr Nephrol 38:2171\u20132178. https:\/\/doi.org\/10.1007\/s00467-022-05828-3","journal-title":"Pediatr Nephrol"},{"key":"6634_CR75","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00467-020-04484-9","volume":"35","author":"AW-M Choi","year":"2020","unstructured":"Choi AW-M, Fong N-C, Li VW-Y, Ho T-W, Chan EY-H, Ma AL-T, Cheung Y-F (2020) Left ventricular stiffness in paediatric patients with end-stage kidney disease. Pediatr Nephrol 35:1051\u20131060. https:\/\/doi.org\/10.1007\/s00467-020-04484-9","journal-title":"Pediatr Nephrol"},{"key":"6634_CR76","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00467-017-3649-9","volume":"33","author":"EY Chan","year":"2018","unstructured":"Chan EY, Warady BA (2018) Acquired cystic kidney disease: an under-recognized condition in children with end-stage renal disease. Pediatr Nephrol 33:41\u201351. https:\/\/doi.org\/10.1007\/s00467-017-3649-9","journal-title":"Pediatr Nephrol"},{"key":"6634_CR77","doi-asserted-by":"publisher","unstructured":"Chan EY, Warady BA (2017) Acquired cystic kidney disease. In: Warady B, Schaefer F, Alexander S (eds) Pediatric Dialysis Case Studies: A Practical Guide to Patient Care. Springer, pp335\u2013341. https:\/\/doi.org\/10.1007\/978-3-319-55147-0","DOI":"10.1007\/978-3-319-55147-0"},{"key":"6634_CR78","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s00467-020-04788-w","volume":"36","author":"EY-H Chan","year":"2021","unstructured":"Chan EY-H, Ma AL-T, Tullus K (2021) When should we start and stop ACEi\/ARB in paediatric chronic kidney disease? Pediatr Nephrol 36:1751\u20131764. https:\/\/doi.org\/10.1007\/s00467-020-04788-w","journal-title":"Pediatr Nephrol"},{"key":"6634_CR79","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00467-022-05762-4","volume":"38","author":"A Trautmann","year":"2023","unstructured":"Trautmann A, Seide S, Lipska-Zi\u0119tkiewicz BS, Ozaltin F, Szczepanska M, Azocar M, Jankauskiene A, Zurowska A, Caliskan S, Saeed B (2023) Outcomes of steroid-resistant nephrotic syndrome in children not treated with intensified immunosuppression. Pediatr Nephrol 38:1499\u20131511","journal-title":"Pediatr Nephrol"},{"key":"6634_CR80","doi-asserted-by":"publisher","unstructured":"Chan EY-h, Sinha A, Ellen L, Akhtar N, Angeletti A, Bagga A, Banerjee S, Boyer O, Chan C-Y, Francis A (2024) An international, multi-center study evaluated rituximab therapy in childhood steroid-resistant nephrotic syndrome. Kidney Int 10:S0085\u20132538(24)00700\u20132. https:\/\/doi.org\/10.1016\/j.kint.2024.09.011","DOI":"10.1016\/j.kint.2024.09.011"},{"key":"6634_CR81","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/apa.14582","volume":"108","author":"E Nattes","year":"2019","unstructured":"Nattes E, Karaa D, Dehoux L, Peuchmaur M, Kwon T, Desch\u00eanes G (2019) Remission of proteinuria in multidrug-resistant idiopathic nephrotic syndrome following immunoglobulin immunoadsorption. Acta Paediatr 108:757\u2013762","journal-title":"Acta Paediatr"},{"key":"6634_CR82","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s13287-022-03112-7","volume":"13","author":"W Morello","year":"2022","unstructured":"Morello W, Budelli S, Bernstein DA, Montemurro T, Montelatici E, Lavazza C, Ghio L, Edefonti A, Peruzzi L, Molino D (2022) First clinical application of cord blood mesenchymal stromal cells in children with multi-drug resistant nephrotic syndrome. Stem Cell Res Ther 13:420","journal-title":"Stem Cell Res Ther"},{"key":"6634_CR83","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.kint.2023.10.006","volume":"103","author":"G Malakasioti","year":"2023","unstructured":"Malakasioti G, Iancu D, Milovanova A, Tsygin A, Horinouchi T, Nozu K, Kamei K, Fujinaga S, Iijima K, Sinha R (2023) A multicenter retrospective study of calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene variants. Kidney Int 103:962\u2013972. https:\/\/doi.org\/10.1016\/j.kint.2023.10.006","journal-title":"Kidney Int"},{"key":"6634_CR84","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.kint.2022.04.029","volume":"102","author":"S Drovandi","year":"2022","unstructured":"Drovandi S, Lipska-Zi\u0119tkiewicz BS, Ozaltin F, Emma F, Gulhan B, Boyer O, Trautmann A, Xu H, Shen Q, Rao J (2022) Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary Coenzyme Q10 deficiency. Kidney Int 102:604\u2013612","journal-title":"Kidney Int"},{"key":"6634_CR85","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1056\/NEJMoa2202396","volume":"388","author":"O Egbuna","year":"2023","unstructured":"Egbuna O, Zimmerman B, Manos G, Fortier A, Chirieac MC, Dakin LA, Friedman DJ, Bramham K, Campbell K, Knebelmann B (2023) Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants. N Eng J Med 388:969\u2013979","journal-title":"N Eng J Med"},{"key":"6634_CR86","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ekir.2022.10.030","volume":"8","author":"W Morello","year":"2023","unstructured":"Morello W, Proverbio E, Puccio G, Montini G (2023) A systematic review and meta-analysis of the rate and risk factors for post-transplant disease recurrence in children with steroid resistant nephrotic syndrome. Kidney Int Rep 8:254\u2013264","journal-title":"Kidney Int Rep"},{"key":"6634_CR87","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1681\/ASN.2013080852","volume":"25","author":"WY Ding","year":"2014","unstructured":"Ding WY, Koziell A, McCarthy HJ, Bierzynska A, Bhagavatula MK, Dudley JA, Inward CD, Coward RJ, Tizard J, Reid C (2014) Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence. J Am Soc Nephrol 25:1342","journal-title":"J Am Soc Nephrol"},{"issue":"11\u201316","key":"6634_CR88","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.jpeds.2022.10.005","volume":"254","author":"H Takao","year":"2023","unstructured":"Takao H, Nishi K, Funaki T, Inoki Y, Osaka K, Nada T, Yokota S, Sato M, Ogura M, Ishikura K (2023) Changes in patterns of infection associated with pediatric idiopathic nephrotic syndrome: a single-center experience in Japan. J Pediatr 254(11\u201316):e11","journal-title":"J Pediatr"},{"key":"6634_CR89","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00467-021-05330-2","volume":"37","author":"W Morello","year":"2022","unstructured":"Morello W, Vianello FA, Proverbio E, Peruzzi L, Pasini A, Montini G (2022) COVID-19 and idiopathic nephrotic syndrome in children: systematic review of the literature and recommendations from a highly affected area. Pediatr Nephrol 37:757\u2013764","journal-title":"Pediatr Nephrol"},{"key":"6634_CR90","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s00467-021-05386-0","volume":"37","author":"C C\u00e9bron","year":"2022","unstructured":"C\u00e9bron C, Godron-Dubrasquet A, Aladjidi N, Roussey G, Boyer O, Avramescu M, Baudouin V, Terzic J, Allain-Launay E, Rieux-Laucat F (2022) Benign and malignant proliferation in idiopathic nephrotic syndrome: a French cohort study. Pediatr Nephrol 37:1837\u20131843","journal-title":"Pediatr Nephrol"},{"key":"6634_CR91","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1007\/s00467-024-06370-0","volume":"39","author":"CH Robinson","year":"2024","unstructured":"Robinson CH, Aman N, Banh T, Brooke J, Chanchlani R, Dhillon V, Langlois V, Levin L, Licht C, McKay A (2024) Impact of childhood nephrotic syndrome on obesity and growth: a prospective cohort study. Pediatr Nephrol 39:2667\u20132677","journal-title":"Pediatr Nephrol"},{"key":"6634_CR92","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s40620-021-01111-0","volume":"35","author":"M-S Meuleman","year":"2022","unstructured":"Meuleman M-S, Guilmin-Cr\u00e9pon S, Hummel A, Daugas E, Dumas A, Leye F, Dantal J, Rigothier C, Provot F, Chauveau D (2022) Long-term health-related quality of life outcomes of adults with pediatric onset of frequently relapsing or steroid-dependent nephrotic syndrome. J Nephrol 35:1123\u20131134","journal-title":"J Nephrol"},{"key":"6634_CR93","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1007\/s00431-023-05135-5","volume":"182","author":"F Veltkamp","year":"2023","unstructured":"Veltkamp F, Teela L, Luijten MA, van Oers HA, Mak-Nienhuis EM, Haverman L, Bouts AH (2023) Health-related quality of life of children with first onset steroid-sensitive nephrotic syndrome. Eur J Pediatr 182:4605\u20134614","journal-title":"Eur J Pediatr"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06634-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-024-06634-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06634-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T07:04:00Z","timestamp":1750748640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-024-06634-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":93,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6634"],"URL":"https:\/\/doi.org\/10.1007\/s00467-024-06634-9","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,26]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"There is no financial disclosure.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}